The CannMed 23 Innovation

& Investment Summit is an

exclusive, invite-only event,
designed for industry
thought leaders.

Since 2016, CannMed

has consistently announced
breakthrough technologies
to the world.

BE THERE WHEN IT HAPPENS.

Image credit: EPM

Dr. Raphael Mechoulam - 2019
EPM, Head of Research - Hebrew
University, Jerusalem

In collaboration with EPM, discovered a

stable form of cannabinoid acids, finally
enabling pharmaceutical development.
WHY CANNMED
Dr. Staci Gruber - 2022
McLean Hospital, Brain Imaging
Center, Harvard Medical School CannMed is the leading forum for
introducing the latest advances
Announced results from the first in medicinal plant science, break-
open-label clinical trial for the treat-
ment of anxiety with CBD. ing the news on scientific discov-
eries that have deeply affected
the course of history.
Kevin McKernan - 2022
Chief Scientific Officer, Medicinal
Genomics
It is now the industry’s must
attend event, where the latest
Sequenced and annotated the 1st advances in technology, innova-
reference genome for 80+ magic
mushroom species. tion, and clinical applications are
first announced to the world.
Dr. David Meiri - 2022
Laboratory of Cancer Biology &
Cannabinoid Research - Technion

Isolated novel cannabinoids that shrink

brain tumors in mice, opening new
promising lines of inquiry.
A COMMUNITY FOR CHANGE

We founded CannMed on the principle

of helping others, prioritizing 
science, and driving change.
 
More than an event, CannMed is a com-
munity of like-minded individuals who
come together to advance medicinal
plant science. 

CannMed provides a truly 

innovative forum where researchers,
physicians, patients, entrepreneurs,
and investors from around the world
share their ground-breaking work. 

And together, we have the power to

turn these ideas into action for the 
betterment of all. 
 PLEASE
JOIN US.

SCAN HERE FOR

VIP REGISTRATION

www.cannmedevents.com